Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

2.

Cancer drug resistance: an evolving paradigm.

Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG.

Nat Rev Cancer. 2013 Oct;13(10):714-26. doi: 10.1038/nrc3599. Review.

PMID:
24060863
3.

Drug resistance in the mouse cancer clinic.

Rottenberg S, Borst P.

Drug Resist Updat. 2012 Feb-Apr;15(1-2):81-9. doi: 10.1016/j.drup.2012.01.001. Epub 2012 Feb 14. Review.

4.

Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis.

Donnenberg VS, Donnenberg AD.

J Clin Pharmacol. 2005 Aug;45(8):872-7. Review.

PMID:
16027397
5.

Biochemical and clinical aspects of efflux pump related resistance to anti-cancer drugs.

Aszalos A, Ross DD.

Anticancer Res. 1998 Jul-Aug;18(4C):2937-44. Review.

PMID:
9713488
6.

Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1.

Liu T, Xu F, Du X, Lai D, Liu T, Zhao Y, Huang Q, Jiang L, Huang W, Cheng W, Liu Z.

Mol Cell Biochem. 2010 Jul;340(1-2):265-73. doi: 10.1007/s11010-010-0426-5. Epub 2010 Mar 12.

PMID:
20224986
7.

Multidrug resistance in cancer: role of ATP-dependent transporters.

Gottesman MM, Fojo T, Bates SE.

Nat Rev Cancer. 2002 Jan;2(1):48-58. Review.

PMID:
11902585
8.
9.
10.

Monitoring of cellular resistance to cancer chemotherapy.

Krishan A, Arya P.

Hematol Oncol Clin North Am. 2002 Apr;16(2):357-72, vi. Review.

PMID:
12094476
11.

ABCG2: the key to chemoresistance in cancer stem cells?

An Y, Ongkeko WM.

Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1529-42. doi: 10.1517/17425250903228834. Review.

PMID:
19708828
12.

Chemoresistance in gliomas.

Lu C, Shervington A.

Mol Cell Biochem. 2008 May;312(1-2):71-80. doi: 10.1007/s11010-008-9722-8. Epub 2008 Feb 8. Review.

PMID:
18259841
13.

Epithelial-mesenchymal transition and drug resistance: role, molecular mechanisms, and therapeutic strategies.

Sui H, Zhu L, Deng W, Li Q.

Oncol Res Treat. 2014;37(10):584-9. doi: 10.1159/000367802. Epub 2014 Sep 16. Review.

PMID:
25342509
14.

Tumour stem cells and drug resistance.

Dean M, Fojo T, Bates S.

Nat Rev Cancer. 2005 Apr;5(4):275-84. Review.

PMID:
15803154
15.

Novel mechanisms of drug resistance in leukemia.

Ross DD.

Leukemia. 2000 Mar;14(3):467-73. Review.

PMID:
10720143
16.

Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells.

Nathwani SM, Butler S, Fayne D, McGovern NN, Sarkadi B, Meegan MJ, Lloyd DG, Campiani G, Lawler M, Williams DC, Zisterer DM.

Cancer Chemother Pharmacol. 2010 Aug;66(3):585-96. doi: 10.1007/s00280-009-1200-9. Epub 2009 Dec 18.

PMID:
20020128
17.

Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges.

Zhang D, Fan D.

Expert Rev Anticancer Ther. 2007 Oct;7(10):1369-78. Review.

PMID:
17944563
18.

Cancer stem cells and chemosensitivity.

Maugeri-SaccĂ  M, Vigneri P, De Maria R.

Clin Cancer Res. 2011 Aug 1;17(15):4942-7. doi: 10.1158/1078-0432.CCR-10-2538. Epub 2011 May 27.

19.

The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies.

Kuwano M, Uchiumi T, Hayakawa H, Ono M, Wada M, Izumi H, Kohno K.

Cancer Sci. 2003 Jan;94(1):9-14. Review.

20.

Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs.

Breedveld P, Beijnen JH, Schellens JH.

Trends Pharmacol Sci. 2006 Jan;27(1):17-24. Epub 2005 Dec 5. Review.

PMID:
16337012
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk